New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 5, 2014
09:24 EDTMNKD, ARNAMannKind shares may fall after Afrezza approval, Feuerstein says
MannKind (MNKD) shares are likely to go higher into the July 15 FDA decision on Afrezza, but are likely to sell off following the drug's approval, The Street's Adam Feuerstein argues. Feuerstein lays out similarities between MannKind and Arena Pharmaceuticals (ARNA). Reference Link
News For MNKD;ARNA From The Last 14 Days
Check below for free stories on MNKD;ARNA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 25, 2014
05:51 EDTMNKDStocks with implied volatility movement; MNKD IGT
Stocks with implied volatility movement; MannKind (MNKD) 97, International Game (IGT) 14 according to iVolatility.
July 24, 2014
14:43 EDTMNKDTourbillon sees potential for MannKind shares to drop 90%, CNBC reports
Subscribe for More Information
July 21, 2014
08:11 EDTARNAArena Pharma' subsidiary enters into agreement for Belviq with Teva subsidiary
Subscribe for More Information
July 18, 2014
16:03 EDTMNKDOptions Update; July 18, 2014
Subscribe for More Information
11:47 EDTMNKDStocks with call strike movement; BBRY MNKD
Subscribe for More Information
July 16, 2014
11:53 EDTMNKDStocks with call strike movement; MNKD SUNE
MannKind (MNKD) January 17 call option implied volatility increased 6% to 79, SunEdison (SUNE) October 28 call option implied volatility increased 3% to 58 according to IVolatility.
09:37 EDTARNAActive equity options trading on open
Subscribe for More Information
July 15, 2014
16:34 EDTARNAArena Pharmaceuticals granted patent for Cannabinoid Receptor Modulators
Arena Pharmaceuticals announced that it was granted U.S. Patent No. 8,778,950, entitled "Cannabinoid Receptor Modulators," by the U.S. Patent and Trademark Office for APD371, an agonist of the cannabinoid receptor 2. Arena is exploring several potential indications for APD371, including chronic pain, and is currently conducting a Phase 1 single-ascending dose trial.
10:40 EDTARNAArena Pharmaceuticals receives USPTO patent for cannabinoid receptor modulators
Reference Link
July 11, 2014
11:33 EDTMNKDStocks with call strike movement; MNKD SUNE
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use